MicroRNAs are both relevant molecular targets and therapeutic targets in cancer. Diverse synthetic antagonists have been developed and can be used to target miRNAs in vivo. The delivery of miRNA mimics and inhibitors to specific organs is still a therapeutic challenge. A liposome-based miR-34 mimic is the first cancer-targeted microRNA drug to enter phase I clinical trials in human patients.